CBSA had a busy legislative session advocating on behalf the industry against transparency measures that stood to stifle bioscience innovation in Colorado and failed to provide the relief patients need next time they pick up a prescription or schedule a procedure. On behalf of the Colorado BioScience Association, our members, and the bioscience industry, we thank the Colorado General Assembly and those leaders who opposed the harmful transparency measures.

Over the past 5 days, CBSA testified in opposition to HB18-1358, Health Care Charges Billing Required Disclosures; HB 1260, Prescription Drug Price Transparency and HB18-1009 – Diabetes Drug Pricing Transparency Act 2018. All three bills died in committee.

At CBSA we are dedicated to patients; to helping people live longer, healthier lives. That’s why we advocate for a holistic, collaborative approach to the drug price conversation. We are committed to working over the summer with the Colorado General Assembly on solutions to help ensure patients have affordable access to therapies and needed medicines.

CBSA ADVOCATING AT THE CAPITOL – WHERE ARE WE TODAY?

With 3 working days left of the legislative session CBSA continues to work to advance legislation that improves the business, workforce and industry growth strategies in the State as well as address bills which stand to have a negative impact on the industry. Below is an update on where legislation stands.

CBSA SUPPORTS

• HB18-1135 – Extend Advanced Industry Export Acceleration Program (CBSA testified)
  • Status: Passed, to be sent to Governor
    
    
• HB18-1185 – Market Sourcing for Business Income Tax Apportionment
  • Status: Referred un-amended – consent calendar to senate committee of the whole
    
    
• HB18-1284 – Disclosure of Prescription Costs at Pharmacies (CBSA testified)
  • Status: Governor signed
    
    
• HB18-1316 – Extend Colorado Department of Labor and Employment Skilled Worker, Outreach, Recruitment, and Key Training Grant Program
  • Status: Referred amended to Senate Committee of the Whole
    
    
• SB18-022 – Clinical Practice for Opioid Prescribing
  • Status: introduced in house – assigned to health, insurance, & environment
    
    
• SB18-042 – Concerning the creation of the agricultural workforce development program
  • Status: House third reading passed, to be sent to Governor


CBSA OPPOSES
• HB18-1009 – Diabetes Drug Pricing Transparency Act 2018 (CBSA testified)
  • Status: postponed indefinitely
    
    
• HB18-1260 – Prescription Drug Price Transparency (CBSA testified)
  • Status: postponed indefinitely
    
    
• HB18-1298 – Colorado Secure Savings Plan
  • Status: postponed indefinitely
    
    
• HB18-1358 – Health Care Charges Billing Required Disclosures(CBSA testified)
  • Status: postponed indefinitely
    
    
• SB18-023 – Promote Off-label Use Pharmaceutical Products
  • Status: postponed indefinitely
    
    
• SB18 – 080 – Wholesale Canadian Drug Importation Program
  • Status: postponed indefinitely
    
    

CBSA NEUTRAL
• HB18-1128: Protections for Consumer Data Privacy
  • Status: Senate third reading passed,to be sent to Governor
    
    
• SB18-152: Prohibit Price Gouging on Prescription Drugs
  • Status: postponed indefinitely
    
    
• HB18-1179: Prohibit Price Gouging on Prescription Drug
  • Status: Laid Over to 08/31/2018, i.e. died